OBJECTIVE To study the general situation and characteristics of the adverse drug reactions(ADRs)associated with polatuzumab vedotin(combined with bendamustine and rituximab),so as to provide reference for clinical rational drug use.METHODS The clinical data of all patients who were hospitalized at Tianjin Cancer Hospital Airport Hospital and treated with polatuzumab vedotin during hospitalization from January 2021 to August 2022 were collected by searching Hospital Information System.The basic patient information,medication status,incidence of adverse reactions,etc,were collected and analyzed.RESULTS A total of 7 patients were enrolled in the analysis,which there were 4 males(57.1％)and 3 females(42.8％).The toxicity profile of polatuzumab vedotin consisted mainly of neutropenia and leukopenia.ADRs mainly occured within 3 months after administration,and it could be recovered after symptomatic treatment or observation,and there was no death due to ADRs.CONCLUSION During the rational use of polatuzumab vedotin in clinical practice,clinicians and pharmacists should reinforce the monitoring on its using to ensure the safe and effective of polatuzumab vedotin clinical application.
关键词
泊洛妥珠单抗/不良反应/回顾性分析
Key words
polatuzumab vedotin/adverse drug reactions(ADR)/retrospective analysis
维普
万方数据